| scholarly article | Q13442814 |
| P2093 | author name string | Jennifer R Brown | |
| P2860 | cites work | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 |
| Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies | Q28817964 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 | ||
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial | Q33438825 | ||
| Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial | Q33439818 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients | Q36273066 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. | Q36920433 | ||
| Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. | Q37097096 | ||
| Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment | Q37706530 | ||
| Management of adverse events associated with idelalisib treatment: expert panel opinion | Q38366294 | ||
| BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia | Q38729031 | ||
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. | Q39416260 | ||
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 | ||
| PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma | Q41994564 | ||
| The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia | Q43090573 | ||
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial | Q47300370 | ||
| Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies | Q47388561 | ||
| Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy | Q47664480 | ||
| Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. | Q48189581 | ||
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. | Q48310393 | ||
| Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience | Q50044415 | ||
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis | Q50054062 | ||
| Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia. | Q50113330 | ||
| Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. | Q51246643 | ||
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | Q52644817 | ||
| Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia | Q57169180 | ||
| Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival | Q80709731 | ||
| Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study | Q86625695 | ||
| How and when I do allogeneic transplant in CLL | Q88645380 | ||
| Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib | Q88804876 | ||
| High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies | Q89574567 | ||
| P433 | issue | 1 | |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 248-255 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | Relapsed CLL: sequencing, combinations, and novel agents | |
| P478 | volume | 2018 |
| Q92995778 | Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications |
| Q92169103 | On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL |
| Q64082232 | Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy? |
Search more.